Braveheart Bio
Phase 3Advancing treatments to improve outcomes and quality of life for patients with hypertrophic cardiomyopathy and related heart conditions.
Founded
2021
Focus
CardiovascularMetabolic
About
Advancing treatments to improve outcomes and quality of life for patients with hypertrophic cardiomyopathy and related heart conditions.
Funding History
1Total raised: $185M
Venture$185MUndisclosedNov 5, 2025
Company Info
TypePrivate
Founded2021
LocationBoston, United States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile